Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme

Article Medicine, General & Internal

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial

Dominik Dahl et al.

Summary: The addition of tirzepatide to insulin glargine treatment in patients with type 2 diabetes resulted in significant improvements in glycemic control after 40 weeks.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Add to Collection

Review Medicine, General & Internal

Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation

Ildiko Lingvay et al.

Summary: Obesity is recognized as a disease associated with serious morbidity and increased mortality. Weight loss has been shown to improve glucose control in patients with type 2 diabetes, as well as reduce risk factors for cardiometabolic disease and improve quality of life.

LANCET (2022)

Add to Collection

Article Endocrinology & Metabolism

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Karan Vadher et al.

Summary: This study compared the efficacy of tirzepatide and semaglutide in patients with type 2 diabetes through an adjusted indirect treatment comparison. The results showed that tirzepatide 10 and 15 mg were significantly better than semaglutide 2 mg in reducing HbA1c and body weight, while there was no significant difference between tirzepatide 5 mg and semaglutide 2 mg.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Adipose Tissue Secretion Pattern Influences β-Cell Wellness in the Transition from Obesity to Type 2 Diabetes

Giuseppina Biondi et al.

Summary: This review summarises the impact of obesity on beta-cell dysfunction, focusing on the natural history of beta-cell failure in obesity-induced T2D and the influence of AT secretome on beta-cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Endocrinology & Metabolism

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Tim Heise et al.

Summary: Tirzepatide demonstrates remarkable glucose-lowering ability in patients with type 2 diabetes by improving insulin secretion and sensitivity. Compared to other GLP-1 receptor agonists, Tirzepatide shows more significant improvements in glucose metabolism.

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

Nobuya Inagaki et al.

Summary: Tirzepatide showed superior efficacy in glycemic control and reduction in body weight compared to dulaglutide, suggesting a potential therapeutic use in Japanese patients with type 2 diabetes.

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

Summary: The American Diabetes Association and the European Association for the Study of Diabetes have updated the consensus statements on the management of hyperglycemia in adults with type 2 diabetes. The new recommendations highlight the importance of social determinants of health, weight management, and provide practical tips for implementation.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Melissa K. Thomas et al.

Summary: Tirzepatide demonstrated significantly greater improvements in insulin sensitivity and beta-cell function compared to dulaglutide, with only partial contributions from weight loss. The dual receptor agonism of tirzepatide may confer distinct mechanisms of glycemic control beyond just weight reduction.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato et al.

Summary: In this study comparing Tirzepatide and glargine in patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications, Tirzepatide demonstrated greater reduction in HbA(1c) and lower incidence of hypoglycemia at week 52, with no excess cardiovascular risk observed compared to glargine.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock et al.

Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik et al.

Summary: The study aimed to compare the efficacy and safety of tirzepatide versus titrated insulin degludec in the treatment of type 2 diabetes. The results showed that tirzepatide had significant advantages in reducing HbA(1c) and bodyweight, and decreased the risk of hypoglycemia.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frias et al.

Summary: The study showed that Tirzepatide was both noninferior and superior to Semaglutide in terms of the mean change in glycated hemoglobin levels for patients with type 2 diabetes over 40 weeks. Additionally, reductions in body weight were greater with Tirzepatide compared to Semaglutide, with similar rates of gastrointestinal adverse events reported in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems